Another group examined the combination of sunitinib with CAR-T therapy targeted at CAIX in a mouse metastatic xenograft RCC model, demonstrating that while sunitinib or the CAIX CAR-T alone had limited anti-tumor effect, the combination decreased tumor burden and prolonged survival [50]. The gene discussed is CA9; the disease is renal cell carcinoma.